NASDAQ:BCRX - BioCryst Pharmaceuticals Stock Price, Forecast & News

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.03. The biotechnology company earned $1.78 million during the quarter, compared to the consensus estimate of $4.54 million. BioCryst Pharmaceuticals had a negative net margin of 1,129.38% and a negative return on equity of 2,511.40%. View BioCryst Pharmaceuticals' Earnings History.

BioCryst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for BioCryst Pharmaceuticals.

8 equities research analysts have issued twelve-month price targets for BioCryst Pharmaceuticals' shares. Their forecasts range from $4.00 to $15.00. On average, they expect BioCryst Pharmaceuticals' share price to reach $8.93 in the next year. This suggests a possible upside of 234.4% from the stock's current price. View Analyst Price Targets for BioCryst Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioCryst Pharmaceuticals.

News coverage about BCRX stock has trended somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioCryst Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals saw a increase in short interest in October. As of October 31st, there was short interest totalling 15,750,000 shares, an increase of 13.0% from the September 30th total of 13,940,000 shares. Based on an average daily volume of 1,440,000 shares, the days-to-cover ratio is presently 10.9 days. Approximately 14.5% of the company's shares are short sold. View BioCryst Pharmaceuticals' Current Options Chain.

Some companies that are related to BioCryst Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include El Pollo LoCo (LOCO), Idera Pharmaceuticals (IDRA), Inovio Pharmaceuticals (INO), Virtu Financial (VIRT), Advanced Micro Devices (AMD), La Jolla Pharmaceutical (LJPC), Alcoa (AA), Exelixis (EXEL), Sangamo Therapeutics (SGMO) and Macrocure (MCUR).

BioCryst Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (3.28%), Point72 Asset Management L.P. (2.20%), First Midwest Bank Trust Division (0.37%), Squarepoint Ops LLC (0.24%), Rhumbline Advisers (0.16%) and Russell Investments Group Ltd. (0.15%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Jon P Stonehouse, Kenneth B Lee Jr, Lynne Powell, Megan Sniecinski, Steve Aselage, Thomas R Staab II and William P Sheridan. View Institutional Ownership Trends for BioCryst Pharmaceuticals.

BCRX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Voloridge Investment Management LLC and First Midwest Bank Trust Division. Company insiders that have sold BioCryst Pharmaceuticals company stock in the last year include Lynne Powell, Thomas R Staab II and William P Sheridan. View Insider Buying and Selling for BioCryst Pharmaceuticals.

BCRX stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Squarepoint Ops LLC, Russell Investments Group Ltd., Public Employees Retirement System of Ohio, Redmile Group LLC, California Public Employees Retirement System, Virtu Financial LLC and Rhumbline Advisers. Company insiders that have bought BioCryst Pharmaceuticals stock in the last two years include Alane P Barnes, Jon P Stonehouse, Kenneth B Lee Jr, Megan Sniecinski and Steve Aselage. View Insider Buying and Selling for BioCryst Pharmaceuticals.

Shares of BCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BCRX stock can currently be purchased for approximately $2.67.

BioCryst Pharmaceuticals has a market capitalization of $396.15 million and generates $20.65 million in revenue each year. The biotechnology company earns $-101,250,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. BioCryst Pharmaceuticals employs 100 workers across the globe.View Additional Information About BioCryst Pharmaceuticals.

The official website for BioCryst Pharmaceuticals is http://www.biocryst.com/.

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company can be reached via phone at 919-859-1302 or via email at [email protected]